TNYA:NASDAQTenaya Therapeutics, Inc. Analysis

Tenaya Therapeutics (TNYA) is trading near its technical support at $0.655 with a bullish MACD histogram (+0.007) despite a broader bearish SMA alignment (20‑day SMA < 50‑day SMA < 200‑day SMA). The stock exhibits extreme volatility (84% 30‑day) and a high beta (~2.7), indicating sharp price swings. Recent material news includes a $55.8 M financing round extending cash runway into H2 2027, a Q4 EPS of $0.12 in line with expectations, and promising early‑stage data from the RIDGE‑1 trial of its TN‑401 gene therapy, all of which have fueled a "strong_buy" consensus among analysts.
Fundamentally, the company has no revenue and negative cash flow, but holds $100 M in cash against modest debt, yielding a price‑to‑book of 1.35 and a forward P/E of –1.7. The combination of a deep cash moat, pipeline momentum, and a market price far below the analyst mean target ($9) suggests significant upside potential, albeit tempered by the inherent clinical‑stage risk and a pronounced downside capture of ~‑74% historically.